Commercial Leqembi sales grow again after subcutaneous approvals PharmaphorumBiogen/Eisai's Alzheimer's drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations.NeuroscienceRead full story pharminent July 29, 2026 (Last updated: July 30, 2026) Pharmaphorum Biogen/Eisai’s Alzheimer’s drug Leqembi continued to grow in Q2, driven by a new subcutaneous version, but fell a little short of expectations. Neuroscience Read full story Post navigation Previous: Eisai and CORE Biomedicine agree on global licence for oncology pipelineNext: Vertex, AbCellera Partner on Next-Generation T-Cell Engagers for Autoimmune Disease Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026